<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95935">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02098356</url>
  </required_header>
  <id_info>
    <org_study_id>2012-480</org_study_id>
    <nct_id>NCT02098356</nct_id>
  </id_info>
  <brief_title>Comparison of High Versus Low Bicarbonate Hemodialysis</brief_title>
  <official_title>Intradialytic Acid-base Changes and Organic Anion Production With High Versus Low Bicarbonate Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine of Yeshiva University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Einstein College of Medicine of Yeshiva University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare hemodialysis treatment with a standard, high-bicarbonate dialysis
      bath versus a lower bicarbonate dialysis bath, and will compare intradialytic acid-base
      changes and overall control of metabolic acidosis with the 2 treatment regimens.   These
      parameters will be assessed in patients currently receiving high-bicarbonate hemodialysis as
      part of usual care.  They will then be switched to a lower bicarbonate prescription, after
      which these parameters will be reassessed.  The study will also examine changes in
      inflammatory markers, glycemic control, ketogenesis, and lipolysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pre-dialysis serum bicarbonate</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum beta-hydroxybutyrate</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta-hydroxybutyrate clearance</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin-6</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum free fatty acids</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recover from dialysis</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis symptom questionnaire</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>End-stage Renal Disease</condition>
  <condition>Metabolic Acidosis</condition>
  <arm_group>
    <arm_group_label>Low bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Bicarbonate</intervention_name>
    <description>Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate</description>
    <arm_group_label>Low bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18

          -  Receiving chronic thrice-weekly conventional hemodialysis for at least 6 months

        Exclusion Criteria:

          -  Use of oral alkali within the previous month

          -  Hospitalization within the previous month

          -  Inability to provide written informed consent

          -  Plans for kidney transplant in the next 2 months

          -  Planned change in phosphate binder therapy within the next month

          -  Pregnancy, or planned pregnancy in the next 2 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Abramowitz, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine of Yeshiva University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Abramowitz, MD, MS</last_name>
    <phone>7184308566</phone>
    <email>matthew.abramowitz@einstein.yu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Abramowitz, MD, MS</last_name>
      <phone>718-430-8566</phone>
      <email>matthew.abramowitz@einstein.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Abramowitz, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine of Yeshiva University</investigator_affiliation>
    <investigator_full_name>Matthew Abramowitz</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>dialysis</keyword>
  <keyword>acidosis</keyword>
  <keyword>bicarbonate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
